Equities

Nanogroup SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NNG:WSE

Nanogroup SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)2.60
  • Today's Change0.00 / 0.00%
  • Shares traded44.63k
  • 1 Year change-12.03%
  • Beta0.3025
Data delayed at least 15 minutes, as of Feb 12 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nanogroup SA is a Poland-based company engaged in the biotechnology sector. The Company focuses on the investment in, as well as development of advanced biotechnological projects in the areas of cancer prevention, early diagnosis, targeted cancer therapies and ontological rehabilitation. Its projects portfolio includes NanoVelos, which is responsible for the creation of drug delivery system for proven oncologic medicines to optimize their performance; NanoSanguis, which develops artificial blood to keep alive patients wounded in accidents, as well as a system, named Organ farm, to preserve human organs ex vivo, and NanoThea, which is dedicated to technology that detects cancer cells in early stage.

  • Revenue in PLN (TTM)-6.90k
  • Net income in PLN-6.93m
  • Incorporated2016
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stem Cells Spin SA115.74k-510.92k18.52m1.00--2.8314.19160.00-0.0124-0.01240.00280.15810.01030.0083.43115,740.00-4.52-1.02-4.57-1.0595.9193.18-441.44-50.721.03-133.660.0262---87.06-37.78-237.07------
Medicofarma Biotech SA281.45k-3.06m34.26m24.00--7.20--121.73-0.0450-0.04500.00410.070.019966.640.746911,727.08-21.55-14.96-31.48-18.5938.8036.02-1,085.51-64.020.821-11.710.00--63.14-17.3933.11------
GENOMED SA27.49m3.27m39.64m53.0012.123.189.831.442.482.4820.819.422.215.1712.68509,166.1026.317.5128.798.8165.2462.3311.903.847.51--0.00--2.343.1819.321.9815.97--
Sds Optic SA7.44m-483.71k50.40m41.00--51.32228.836.77-0.0815-0.08151.250.15590.54975.12125.84181,486.60-4.01-32.89-4.24-41.3598.1949.49-7.29-136.622.500.62780.00--40.53301.05-45.06--57.27--
Sygnis SA7.73m-6.34m54.31m12.00--1.69--7.02-0.2499-0.24990.33091.170.1166-0.16896.14218,427.70-9.03-8.61-15.00-12.10108.4959.85-77.44-39.140.6697-0.00660.13---52.2926.88-47.44---9.50--
Read Gene SA15.19m-887.46k60.36m11.00--22.53--3.97-0.0536-0.05361.170.22731.0839.776.30---6.32-2.40-6.88-2.7492.6390.21-5.84-4.306.31-0.6960.00--30.3826.3817.49------
Genomtec SA15.00k-11.01m72.69m----7.02--4,845.79-0.7485-0.74850.0010.68690.0009--0.0143---65.47-89.96-82.11-113.38-54,120.00-4,379.72-73,393.34-17,225.072.82-39.820.1409--0.00-63.42-24.35---34.54--
Hyenergy SA3.29m169.85k77.91m27.00--3.95318.9023.69-0.0936-0.09360.16540.58780.18210.12590.7741--0.94032.391.283.3599.7077.465.163.111.301.170.00--192.8319.47100.30---45.79--
Urteste SA0.00-5.47m81.49m34.00--3.48-----3.88-3.880.0015.350.00-------15.56-29.65-18.99-31.35---45,933.33---623,333.30----0.0128------35.00--197.79--
Nanogroup SA-6.90k-6.93m85.19m----7.30-----0.1844-0.1844-0.00020.3553-0.00032.64-----30.59-29.50-51.55-33.80--66.72---2,258.260.9785-464.180.00--3.96-64.0934.50--3.07--
Poltreg SA0.00-24.56m123.12m33.00--2.49-----5.27-5.270.0010.610.0016.45--0.00-25.87-9.02-29.62-10.18---659.36---854.232.65--0.1365---74.98-6.89-38.06--83.47--
Mabion SA14.81m-59.30m132.21m204.00--1.89--8.93-3.67-3.670.91644.330.09888.1027.2572,602.94-39.560.5366-54.811.06-178.5558.34-400.370.96430.2276--0.04---54.50---115.35--6.00--
Molecure SA5.11m-24.42m152.26m71.00--1.70--29.78-1.20-1.200.24934.340.0553--7.0150,119.41-26.42-3.15-27.53-3.3051.4893.34-477.67-15.45----0.0588---40.47278.20-10.27--12.49--
Data as of Feb 12 2026. Currency figures normalised to Nanogroup SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.